SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. It produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
86
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. SAB Biotherapeutics Inc market cap is $253.15M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. SAB Biotherapeutics Inc 52 week high is $5.15 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. SAB Biotherapeutics Inc 52 week low is $2.44 as of November 22, 2026.
SAB Biotherapeutics Inc stock price today is $2.81.
SAB Biotherapeutics Inc stock price yesterday was $2.91.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. SAB Biotherapeutics Inc's P/E ratio is -1.67.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. SAB Biotherapeutics Inc P/B ratio is 1.2142.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. SAB Biotherapeutics Inc 50-day moving average is $3.07.